AMGEN’S CLINICAL TRIALS

Advancing oncology at the speed of life™
### MULTIPLE MYELOMA

**Pavurutamab (AMG 701)**  
HLE BiTE® platform (HLE BiTE® molecule targeting BCMA)  
- **NCT: 03287908** [Amgen ID*: 20170122]  
- **Status**: Phase 1/2  
- **First-in-Human Study of Pavurutamab in Multiple Myeloma**

**Carfilzomib†**  
Small molecule (proteasome inhibitor)  
- **NCT: 03091127** [Amgen ID*: 20150262]  
- **Status**: Phase 1/2  
- **Real-world Use of Carfilzomib Among Patients With Relapsed MM in Europe**

**Carfilzomib†**  
Small molecule (proteasome inhibitor)  
- **NCT: 03859427** [Amgen ID*: 20180015]  
- **Status**: Phase 3  
- **Study of Once-Weekly vs Twice-Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)**

**Carfilzomib†**  
Small molecule (proteasome inhibitor)  
- **NCT: 03158688** [Amgen ID*: 20160275]  
- **Status**: Phase 3  
- **Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (CANDOR)**

**Carfilzomib†**  
Small molecule (proteasome inhibitor)  
- **NCT: 04191616** [Amgen ID*: 20180117]  
- **Status**: Phase 2  
- **Study of Carfilzomib Plus Pomalidomide and Dexamethasone in Patients With First or Second Relapse of Multiple Myeloma (SELECT)**

### LEUKEMIA

**AMG 330**  
BiTE® platform (BiTE® molecule targeting CD33)  
- **NCT: 02520427** [Amgen ID*: 20120252]  
- **Status**: Phase 1  
- **First-in-Human Study of AMG 330 in Adult Patients With Relapsed or Refractory AML**

**AMG 427**  
HLE BiTE® platform (HLE BiTE® molecule targeting FLT3 antigen)  
- **NCT: 03541369** [Amgen ID*: 20170528]  
- **Status**: Phase 1  
- **First-in-Human Study of AMG 427 in Patients With Relapsed/Refractory AML**

**AMG 176**  
Small molecule (intravenous MCL-1 inhibitor)  
- **NCT: 00675452** [Amgen ID*: 20150161]  
- **Status**: Phase 1  
- **First-in-Human Study of AMG 176 in Relapsed or Refractory AML**

**Blinatumomab**  
BiTE® platform (BiTE® molecule targeting CD19)  
- **NCT: 03117621** [Amgen ID*: 20150136]  
- **Status**: Phase Observational  
- **Observational Study of Blinatumomab**

**Blinatumomab**  
BiTE® platform (BiTE® molecule targeting CD19)  
- **NCT: 04524455** [Amgen ID*: 20190177]  
- **Status**: Phase 1b  
- **Study of Blinatumomab in Combination With AMG 404 in Adults With Relapsed or Refractory B-precursor ALL**

**Blinatumomab**  
BiTE® platform (BiTE® molecule targeting CD19)  
- **NCT: 04521231** [Amgen ID*: 20180257]  
- **Status**: Phase 1b  
- **Study of Subcutaneous Blinatumomab Administration in ALL**

**Blinatumomab**  
BiTE® platform (BiTE® molecule targeting CD19)  
- **NCT: 04506086** [Amgen ID*: 20190014]  
- **Status**: Phase 1b  
- **Study of Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor ALL**

**Blinatumomab**  
BiTE® platform (BiTE® molecule targeting CD19)  
- **NCT: 04994717** [Amgen ID*: 20190360]  
- **Status**: Phase 4  
- **Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia**

**Carfilzomib†**  
Small molecule (proteasome inhibitor)  
- **NCT: 02303821** [Amgen ID*: CFZ008]  
- **Status**: Phase 1b/2  
- **Study of the Safety, Tolerability, and Activity of Carfilzomib, Alone and in Combination With Induction Chemotherapy, in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia**

**ABP 959‡**  
Monoclonal antibody (eculizumab biosimilar)  
- **NCT: 03818607** [Amgen ID*: 20150168]  
- **Status**: Clinical Comparability  
- **Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)**

**Efavaleukin alfa (formerly AMG 592)**  
Fusion protein (IL-2 mutein)  
- **NCT: 03422627** [Amgen ID*: 20160283]  
- **Status**: Phase 1b/2  
- **Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Efavaleukin alfa in Adult Patients With Steroid-Refractory Chronic Graft Versus Host Disease**
### Solid Tumors

#### Gastro/Esophageal Junction Cancer

**Bemarituzumab**
- Monoclonal antibody targeting FGFR2b
- **NCT:** 03694522
- **Amgen ID:** FPA144-004
- **Phase:** 2

**A Phase 2 Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX5 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)**
- **Status:** Active, recruiting

**A Phase 3 Study of Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)**
- **Status:** Not yet recruiting

**A Phase 1b/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric/Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)**
- **Status:** Active, not recruiting

#### Intestinal, Pancreatic, or Colorectal Cancer

**Romiplostim**
- Protein/peptibody (thrombopoiesis stimulator)
- **NCT:** 03362177
- **Amgen ID:** 20140346
- **Phase:** 3

**A Phase 1 Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal, Pancreatic, or Colorectal Cancer**
- **Status:** Active, recruiting

#### Lung Cancer

**Sotorasib (AMG 510)**
- Small molecule (KRASG12C inhibitor)
- **NCT:** 03600883
- **Amgen ID:** 20170543
- **Phase:** 1

**CodeBreka 100: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination Therapy With Anti-PD-1/L1 in NSCLC With KRAS G12C Mutation**
- **Status:** Not yet recruiting

**CodeBreka 101: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With KRAS G12C Mutation**
- **Status:** Potential to resume

**CodeBreka 105: Open-Label Study Evaluating Sotorasib Monotherapy in Patients of Chinese Descent With Advanced Solid Tumors With KRAS G12C Mutation**
- **Status:** Not recruiting

**CodeBreka 200: A Phase 3 Study to Compare Sotorasib With Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC With KRAS G12C Mutation**
- **Status:** Active, recruiting

**CodeBreka 201: Open Label Study of Sotorasib in Untreated Patients with Stage IV KRAS G12C-mutated NSCLC and PDL1 <1% and/or STK11 mutation**
- **Status:** Active, recruiting

**AMG 199**
- HLE BiTE® platform (HLE BiTE® molecule targeting MUC17)
- **NCT:** 04117958
- **Amgen ID:** 20180290
- **Phase:** 1

**A Phase 1 Study Evaluating the Safety and Efficacy of AMG 199 in Combination With AMG 404 in Subjects With SCLC**
- **Status:** Active, recruiting

**AMG 910**
- BiTE® platform (BiTE® molecule targeting CLDN18.2)
- **NCT:** 04260191
- **Amgen ID:** 20180292
- **Phase:** 1

**A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma**
- **Status:** Active, not recruiting

**Acapatamab (AMG 160)**
- HLE BiTE® platform (HLE BiTE® molecule targeting PSMA)
- **NCT:** 04822298
- **Amgen ID:** 20180273
- **Phase:** 1b

**A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer**
- **Status:** Active, recruiting

**Tarlatamab (AMG 757)**
- HLE BiTE® platform (HLE BiTE® molecule targeting DLL3)
- **NCT:** 03319940
- **Amgen ID:** 20190288
- **Phase:** 2

**AMG 910 + AMG 404**
- HLE BiTE® platform (HLE BiTE® molecule targeting DLL3) + Monoclonal antibody (Anti-PD1)
- **NCT:** 03319940
- **Amgen ID:** 20200439
- **Phase:** 1b

**A Phase 1b Study Evaluating the Safety and Efficacy of Tarlatamab (AMG 757) in Combination With AMG 404 in Subjects With SCLC**
- **Status:** Completed, pending results
<table>
<thead>
<tr>
<th>SOLID TUMORS</th>
<th>SOLID TUMORS</th>
<th>VARIOUS SOLID TUMORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NON-SMALL CELL LUNG, OVARIAN, OR BREAST CANCER</strong></td>
<td><strong>SOLID TUMORS WITH KRAS G12C MUTATION</strong></td>
<td><strong>VARIOUS SOLID TUMORS</strong></td>
</tr>
<tr>
<td>Romiplostim</td>
<td>Sotorasib (AMG 510)</td>
<td>AMG 256</td>
</tr>
<tr>
<td>Protein/peptibody (thrombopoiesis stimulator)</td>
<td>Small molecule (KRASG12C inhibitor)</td>
<td>Bi-functional fusion protein (Targeted IL-21 receptor agonist)</td>
</tr>
<tr>
<td>NCT: 03937154 Amgen ID*: 20170770</td>
<td>NCT: 03600883 Amgen ID*: 20170543</td>
<td>NCT: 03462748 Amgen ID*: 20180144</td>
</tr>
<tr>
<td>Status: Active, recruiting</td>
<td>Status: Phase 1/2</td>
<td>Status: Phase 1</td>
</tr>
<tr>
<td>Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Non-small Cell Lung, Ovarian, or Breast Cancer</td>
<td>CodeBreak 100: Open-Label Study Evaluating Sotorasib Monotherapy in Advanced Solid Tumors With KRAS G12C Mutation</td>
<td>A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td><strong>PROSTATE CANCER</strong></td>
<td><strong>AMG 404</strong></td>
<td><strong>AMG 506</strong></td>
</tr>
<tr>
<td>Acapatamab (AMG 160)</td>
<td>Monoclonal antibody (Anti-PD1)</td>
<td>(also known as MP0310) DARPin® protein targeting FAP x 4-1BB</td>
</tr>
<tr>
<td>HLE BiTE® platform (HLE BiTE® molecule targeting PSMA)</td>
<td>NCT: 03790284 Amgen ID*: 20180101</td>
<td>NCT: 04049903 Amgen ID*: 20180143</td>
</tr>
<tr>
<td>Status: Phase 1</td>
<td>Status: Phase 1</td>
<td>Status: Phase 1</td>
</tr>
<tr>
<td>Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab (AMG 160) in Patients With mCRPC</td>
<td>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 404 in Patients With Advanced Solid Tumors</td>
<td>A Phase 1 Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 506 in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>NCT: 04631601 Amgen ID*: 20190505</td>
<td>NCT: 04702737 Amgen ID*: 20200040</td>
<td>NCT: 04293094 Amgen ID*: 20190131</td>
</tr>
<tr>
<td>Status: Active, not recruiting</td>
<td>Status: Phase 1b</td>
<td>Status: Phase 1</td>
</tr>
<tr>
<td>A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)</td>
<td>Study Evaluating Tarlatamab (AMG 757) in Subjects With Metastatic Castration-Resistant Prostate Cancer</td>
<td>A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MP0310 in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td><strong>AMG 340</strong></td>
<td><strong>AMG 509</strong></td>
<td><strong>AMG 650</strong></td>
</tr>
<tr>
<td>UniAb® platform (bispecific T cell engager targeting PSMA and CD3)</td>
<td>XmA® platform (XmA® targeting STEAP1)</td>
<td>Small molecule targeting KIF18A being evaluated in advanced solid tumors</td>
</tr>
<tr>
<td>NCT: 04740034 Amgen ID*: 20210249</td>
<td>NCT: 04221542 Amgen ID*: 20180146</td>
<td>NCT: 04293094 Amgen ID*: 20190131</td>
</tr>
<tr>
<td>Status: Phase 1</td>
<td>Status: Phase 1</td>
<td>Status: Phase 1</td>
</tr>
<tr>
<td>A Study of AMG 340 (TNB-585) in Subjects With Metastatic Castrate-resistant Prostate Carcinoma</td>
<td>Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer</td>
<td>A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors</td>
</tr>
<tr>
<td><strong>Tarlatamab (AMG 757)</strong></td>
<td><strong>AMG 193</strong></td>
<td><strong>AMG193</strong></td>
</tr>
<tr>
<td>HLE BiTE® platform (HLE BiTE® molecule targeting DLL3)</td>
<td>MTA cooperative PRMT5 inhibitor</td>
<td>MTA cooperative PRMT5 inhibitor</td>
</tr>
<tr>
<td>NCT: 04702737 Amgen ID*: 20200040</td>
<td>NCT: 05094336 Amgen ID*: 20210023</td>
<td>NCT: 05094336 Amgen ID*: 20210023</td>
</tr>
<tr>
<td>Status: Phase 1b</td>
<td>Status: Phase 1/1b/2</td>
<td>Status: Phase 1/1b/2</td>
</tr>
<tr>
<td>Study Evaluating Tarlatamab (AMG 757) in Patients With De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer</td>
<td>A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors</td>
<td>A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors</td>
</tr>
</tbody>
</table>
### SOLID TUMORS

**Talimogene Laherparepvec**
*Oncolytic immunotherapy (oncolytic viral therapy)*

<table>
<thead>
<tr>
<th>Study Title</th>
<th>NCT ID</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of Talimogene Laherparepvec in Children With Advanced Non-CNS Tumors</td>
<td>NCT: 02756845</td>
<td>1</td>
<td>R</td>
</tr>
<tr>
<td>Study to Evaluate the Safety/Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma</td>
<td>NCT: 03064763</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Safety Study of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318)</td>
<td>NCT: 02509507</td>
<td>1b/2</td>
<td>R</td>
</tr>
<tr>
<td>Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases</td>
<td>NCT: 04068181</td>
<td>1b</td>
<td>A</td>
</tr>
<tr>
<td>T-VEC With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)</td>
<td>NCT: 02211131</td>
<td>2</td>
<td>A</td>
</tr>
<tr>
<td>Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma</td>
<td>NCT: 02910557</td>
<td>1b</td>
<td>R</td>
</tr>
<tr>
<td>Postmarketing Prospective Study of Melanoma Patients Treated With Talimogene Laherparepvec to Characterize Risk of Herpetic Infection</td>
<td>NCT: 02173171</td>
<td>4</td>
<td>R</td>
</tr>
<tr>
<td>Registry Study to Evaluate the Survival and Long-Term Safety of Patients With Melanoma Who Previously Received Talimogene Laherparepvec</td>
<td>NCT: 02120139</td>
<td>Registry</td>
<td>Observational</td>
</tr>
</tbody>
</table>

**UniAb® Platform**

**XmAb® Bispecific Antibody**
*Oncolytic Viral Therapy*  
*CAR T Cell*

**Small Molecule**  
**BiTE® Technology**  
**HLE BiTE® Technology**  
**DARPin® Peptibody**  
**Monoclonal Antibody**  
**Peptibody**  
**Bi-functional Fusion Protein**  
**Fusion Protein**  
**UniAb® Platform**

---

**MODALITIES**

Amgen has built an array of drug modalities that is unsurpassed in the biopharmaceutical industry.

---

Disclaimer: Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process.
Amgen’s Research and Development Strategy

Our Vision
Benefit patients and societies through transformative medicines.

Our Priorities

Improve our success rates: Focus our people and investments more intensely on the activities most likely to lead to new therapies.

Reduce cycle times: The industry’s standard timeline of 12 to 14 years from project start to drug approval is not viable. Amgen has already reduced its drug development timelines by about three years, but there is still ample room for improvements.

Enable access and use: Gaining regulatory approval for new therapies is only half the battle. In the end, only one metric matters: Are the patients who need Amgen medicines actually getting them?

Our Strategic Imperatives

Make focused investment in innovative research platforms:
- Focus research investments in cardiometabolic, inflammation, and cancer therapeutic areas. Rapidly expand the scale and diversity of our human genetic platform.
- Expand our human data resources to include proteomics, transcriptomics, and allied data to generate deeper insights into disease biology.
- Use our strength in molecular engineering to expand on the success of current drug platforms, including BiTE® molecules, and pioneer novel modalities to address targets now seen as undruggable.

Innovate in clinical development:
- Reduce the durations and cost of clinical trials and improve success rates through greater use of modelling and simulation, adaptive designs, and real-world evidence.
- Design smaller and faster studies with larger response rates by using genetics and omics to identify patients who will potentially benefit most from new therapies.

Address access and use at all stages of drug development:
- Ensure that representatives from our medical, clinical development, commercial, and manufacturing functions are partnering with research teams very early in each drug discovery program to define the attributes a new medicine will need to gain future access and use.
- Leverage our Global Medical organization and its external network of research collaborators to generate insights into the evidence our drug development teams must generate in order to support access and use.
- Invest in biomarkers, diagnostics, and other tools that can enhance the value of our medicines and support Amgen’s commitment to empower doctors to go beyond a traditional “one size fits all” approach to treat patients in a more precise, personalized way.

Our Strategic Enablers
- Maintain our long-standing and successful commitment to continuous improvement and operational efficiency in all aspects of R&D by challenging the way we work, speeding up decision making, and delivering better productivity to free resources to drive our science and innovation to deliver transformative medicines.
- The foundation for our past and future success is our people – they form the foundation for all we do. We will continue to build an R&D culture that recruits, develops, and retains the best talent excited by the opportunities arising from rapid scientific progress and new technologies to push the boundaries of science as part of a collaborative team vested in a collective accountability for our success.